BeiGene

BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II | Markets Insider | Business Insider | 5/15/2020

CAMBRIDGE, Mass., and BEIJING, China, May 15, 2020 (GLOBE NEWSWIRE) – BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-L1 antibody BGB-A333 and preclinical data on three early-stage drug candidates will be presented at the 2020 American Association for …

BeiGene’s new BTK drug Brukinsa falls short as PD-1 tislelizumab shines in busy quarter | FiercePharma | 5/12/2020

… previously treated mantle cell lymphoma (MCL), Brukinsa only sold $720,000 in its first full quarter on the market, way below industry watchers’ expectations of around $7 million. But it’s too soon to pass judgment, BeiGene said . “Early launch indicators including new patient starts, reimbursement coverage, and physician perception have been encouraging,” its first-quarter announcement stated. Survey Report Direct-to-Patient Supply: Industry Perception and Future Trends To better understand …

Follow BeiGene:    

Debbie’s Dream Foundation: Curing Stomach Cancer Announces the Launch of New Dream Makers Miracle Fund for Patients and Their Families | PR Newswire | 5/8/2020

… joy within the stomach cancer community by providing patients and their families with bucket-list inspired experiences. The new program is being made possible thanks to DDF’s newly formed partnership with global biotechnology company BeiGene , Ltd. DDF’s Chief Executive Officer Andrea Eidelman is excited about the new program and looks forward to putting smiles on the faces of stomach cancer patients and their families. “This is a wonderful opportunity for …

BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting | Globe Newswire | 4/30/2020

Developmental Therapeutics—Immunotherapy Poster Session Lead Author Jianming Xu, M.D., General Hospital of Chinese People’s Liberation Army, China About BeiGene BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,500+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics …

Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19 | Globe Newswire | 4/29/2020

Companies to utilize proprietary platforms to discover, develop, and manufacture potential therapeutic antibodies to combat ongoing COVID-19 pandemic - SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. and BEIJING, China and MOUNTAIN VIEW, Calif., April 29, Atreca, Inc. (Nasdaq: BCEL), BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), and IGM Biosciences, Inc. (Nasdaq: IGMS), today announced their plans to collaborate to help address the COVID-19 pandemic. The companies will leverage their combined …

Tracking Baker Brothers Portfolio – Q4 2019 Update | 4/27/2020

Baker Brothers’ 13F portfolio value increased from $14.70B to $18.81B this quarter. Kodiak Sciences stake was increased while decreasing Amarin Corp during the quarter. The top-three positions are Seattle Genetics, Incyte Corporation, and BeiGene and they add up to almost ~55% of the portfolio. This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly basis …

B-cell Non-Hodgkin’s Lymphoma (NHL): Worldwide Market Insights, Epidemiology and Forecast to 2028 - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | Business Wire | 4/24/2020

… based regimen except Rituximab, Immune Checkpoint inhibitors, Immunomodulators, Proteasome inhibitors, Kinase inhibitors, CAR-T cell therapies, and Histone deacetylase (HDAC) inhibitors. The following drugs are approved under abovementioned classes, Brukinsa (Zanubrutinib, a product of BeiGene ), Polivy (Polatuzumab vedotin, a product of Hoffmann-La Roche), Venetoclax (ABT199, a product of AbbVie and Roche), Kymriah (tisagenlecleucel, a product of Novartis), Yescarta (Axicabtagene ciloleucel, a product of Gilead Sciences), Aliqopa (Copanlisib, a product …

Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers | PR Newswire | 4/23/2020

… humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has formed a partnership with BeiGene , Ltd. for the rights to develop DKN-01 in Asia (excluding Japan ), Australia , and New Zealand . For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available …

DNA-Encoded Libraries - 2019 Spending Reached USD182 Billion, with 16,000 Drug Molecules Evaluated | PR Newswire | 4/23/2020

… APPENDIX 1: TABULATED DATA 13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS A selection of the companies mentioned include: AbbVie Abilita Bio Actelion Pharmaceuticals Aduro Biotech Almirall Amgen Asinex Astellas Pharma AstraZeneca BASF Bayer BeiGene Bristol- Myers Squibb BOC Sciences Boehringer Ingelheim Broad Institute ChemAxon ChemRoutes Chem-Space Circle Pharma ComInnex Confo Therapeutics Cyclofluidic Edelris Eli Lilly Enamine Ensemble Therapeutics ETH Zurich Exo therapeutics HitGen HotSpot Therapeutics InterX Technologies Janssen …

China accepts BeiGene application for expanded use of tislelizumab | 4/21/2020

China’s National Medical Products Administration has accepted for review BeiGene’s (NASDAQ: BGNE ) supplemental marketing application seeking approval of PD-1 inhibitor tislelizumab, combined with two chemo regimens, for the treatment of advanced squamous non-small cell lung cancer. Tislelizumab was recently approved there for urothelial cancer, its first in solid tumors. It was first approved in China for certain classical Hodgkin lymphoma patients. https://seekingalpha.com/news/3562284-china-authorities-accept …

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene | 4/21/2020

In Clinical Trials by Barbara Jacoby April 21, 2020 Pinterest From: finance.yahoo.com Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy as a first-line treatment for patients with metastatic HER2-positive breast cancer and in …

Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang Sells 1,500 Shares | Daily Political | 4/20/2020

… also recently made the following trade(s): BGNE opened at $157.43 on Monday. The stock has a market cap of $12.13 billion, a price-to-earnings ratio of -10.00 and a beta of 1.22. Beigene Ltd has a 1 year low of $113.01 and a 1 year high of $210.35. The company has a current ratio of 3.78, a quick ratio of 3.69 and a debt-to-equity ratio of …

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China | Globe Newswire | 4/20/2020

BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) – BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) of BeiGene ’s anti-PD-1 antibody tislelizumab …

Biotech Companies Look To China As Government Politicies Stoke Pharmaceutical Growth | Investor’s Business Daily | 4/20/2020

… overnight,” he said. “In the U.S., that growth for big companies is slowing down because payers are pushing back and launches aren’t as good as they used to be.” Amgen Partners With Biotech Company BeiGene Many expect partnerships to bloom from biotech companies salivating to enter China’s drug market. Amgen was among the first biotech companies to take this leap. In October, Amgen announced a $2.7 billion stake in Beijing …

Nuveen Asset Management LLC Lowers Holdings in Beigene Ltd (NASDAQ:BGNE) | 4/19/2020

Nuveen Asset Management LLC cut its position in Beigene Ltd (NASDAQ:BGNE) by 16.1% during the 4th its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,800 shares of the company’s stock after selling 10,745 shares during the quarter. Nuveen Asset Management LLC owned about 0.09% of Beigene worth $9,249,000 as of its most recent filing with the Securities and Exchange Commission (SEC …

Amgen (NASDAQ:AMGN) Upgraded to Buy by Zacks Investment Research | Daily Political | 4/19/2020

… hurt the same. Amgen boasts a strong biosimilars portfolio. It is also progressing with its pipeline while regularly pursuing “external opportunities” such as the acquisition of Otezla and the recently acquired stake in China’s BeiGene . Amgen also expects several important clinical data readouts from its innovative pipeline in 2020. However, pricing and competitive pressure are concerns. Amgen’s shares have outperformed the industry in the past one year. Estimates have gone …

Jane Huang Sells 1,500 Shares of Beigene Ltd (NASDAQ:BGNE) Stock - Ticker Report | 4/19/2020

… the company’s stock, valued at $46,666,720. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Jane Huang also recently made the following trade(s): Get Beigene alerts: On Tuesday, January 21st, Jane Huang sold 1,500 shares of Beigene stock. The stock was sold at an average price of $170.69, for a total value of $256,035.00. Shares of BGNE opened at $157.43 …

Arden Trust Co Invests $117,000 in Beigene Ltd (NASDAQ:BGNE) - Ticker Report | 4/19/2020

Arden Trust Co acquired a new position in Beigene Ltd (NASDAQ:BGNE) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 944 shares of the company’s stock, valued at approximately $117,000. Several other large investors have also recently made changes to their positions in the company. M&G Investment Management Ltd. raised its stake in shares of Beigene by 130.5 …

Beigene (NASDAQ:BGNE) Price Target Lowered to $184.00 at Morgan Stanley | 4/19/2020

… published on Wednesday, BenzingaRatingsTable reports. They currently have an overweight rating on the stock. Other equities research analysts have also recently issued reports about the stock. Goldman Sachs Group initiated coverage on shares of Beigene in a research report on Tuesday, February 18th. They issued a buy rating and a $197.30 price objective for the company. Maxim Group lowered their price objective on shares of Beigene from $210.00 to $190.00 …

Beigene Ltd (NASDAQ:BGNE) CMO Sells $240,000.00 in Stock | 4/18/2020

… the company’s stock, valued at approximately $46,666,720. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink . Jane Huang also recently made the following trade(s): Get Beigene alerts: On Tuesday, January 21st, Jane Huang sold 1,500 shares of Beigene stock. The stock was sold at an average price of $170.69, for a total transaction of $256,035.00. Beigene stock traded up $0.55 during …

Amgen (NASDAQ:AMGN) Stock Rating Upgraded by Zacks Investment Research | 4/18/2020

… hurt the same. Amgen boasts a strong biosimilars portfolio. It is also progressing with its pipeline while regularly pursuing “external opportunities” such as the acquisition of Otezla and the recently acquired stake in China’s BeiGene . Amgen also expects several important clinical data readouts from its innovative pipeline in 2020. However, pricing and competitive pressure are concerns. Amgen’s shares have outperformed the industry in the past one year. Estimates have gone …

Amgen (NASDAQ:AMGN) Lifted to “Buy” at Zacks Investment Research | 4/18/2020

… hurt the same. Amgen boasts a strong biosimilars portfolio. It is also progressing with its pipeline while regularly pursuing “external opportunities” such as the acquisition of Otezla and the recently acquired stake in China’s BeiGene . Amgen also expects several important clinical data readouts from its innovative pipeline in 2020. However, pricing and competitive pressure are concerns. Amgen’s shares have outperformed the industry in the past one year. Estimates have gone …

Beigene (NASDAQ:BGNE) PT Lowered to $184.00 | Daily Political | 4/17/2020

… overweight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 17.29% from the company’s previous close.Several other research analysts have also recently issued reports on BGNE. ValuEngine raised shares of Beigene from a “hold” rating to a “buy” rating in a report on Tuesday, March 3rd. Zacks Investment Research lowered shares of Beigene from a “hold” rating to a “sell” rating in a research report on …

FiercePharmaAsia—Gilead’s nixed remdesivir trials; Indian pharmas’ site nods; CanSino’s COVID-19 vaccine | FiercePharma | 4/17/2020

… July. The company is considering whether it can improve on its lead candidate by combining different antibodies into a cocktail. It also hopes to develop a “super antibody” capable of neutralizing other coronaviruses. 6. BeiGene ’s PD-1 tislelizumab hits goal in 1st-line lung cancer, cuing Keytruda rivalry (release) BeiGene said a Chinese phase 3 examining its PD-1 tislelizumab in combination with chemo in front-line non-squamous non …

Financial Comparison: Beigene (NASDAQ:BGNE) vs. Akero Therapeutics (NASDAQ:AKRO) | 4/16/2020

… Akero Therapeutics has a consensus target price of $32.33, indicating a potential upside of 56.05%. Given Akero Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Akero Therapeutics is more favorable than Beigene. Institutional and Insider Ownership 75.5% of Beigene shares are held by institutional investors. Comparatively, 66.4% of Akero Therapeutics shares are held by institutional investors. 10.7% of Beigene shares are held by insiders. Strong institutional ownership …

AACR

BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II | Markets Insider | 5/15/2020

… BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-L1 antibody BGB-A333 and preclinical data on three early-stage drug candidates will be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, taking place on …

American Association for Cancer Research

BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II | Markets Insider | 5/15/2020

CAMBRIDGE, Mass., and BEIJING, China, May 15, 2020 (GLOBE NEWSWIRE) – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-L1 antibody BGB-A333 and preclinical data on three early-stage drug candidates will be presented at the 2020 American Association for …

American Society of Clinical Oncology

BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting | Globe Newswire | 4/30/2020

Developmental Therapeutics—Immunotherapy Poster Session Lead Author Jianming Xu, M.D., General Hospital of Chinese People’s Liberation Army, China About BeiGene BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,500+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics …

Clinical Data

BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting | Globe Newswire | 4/30/2020

Developmental Therapeutics—Immunotherapy Poster Session Lead Author Jianming Xu, M.D., General Hospital of Chinese People’s Liberation Army, China About BeiGene BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,500+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics …

Food and Drug Administration

EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients from the SISCO Study | Business Wire | 4/1/2020

… here: https://www.businesswire.com/news/home/20200401005245/en/ Siltuximab is an interleukin (IL)-6 targeted monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as well as in … has exclusive rights to SYLVANT ® globally. EUSA Pharma has granted BeiGene, Ltd., exclusive development and commercialisation rights to SYLVANT ® in Greater China. Indications and Usage of SYLVANT ® - See full Prescribing Information for additional information . SYLVANT …

Big Pharma

#FierceMadness: Big brands and underdogs—Onpattro and Jeuveau included—make the Sweet 16 cut | FiercePharma | 3/30/2020

… of underdogs left standing, with drugs from both big and small pharma companies still in the hunt. Big winners from Big Pharma include AbbVie’s Skyrizi and Roche’s Xofluza, while smaller pharma brands still vying for … tennis player” and “French honors student … sounds lovely!” In Oncology, BeiGene’s Brukinsa posted a win over Bayer’s Nubeqa—a surprise, considering the general love that any “q” names seem to get. In this case, though …

Biotech

Amgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts | PR Newswire | 3/23/2020

… brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars and the Amgen Biotech Experience. For more information, visit AmgenInspires.com and follow us on Twitter @AmgenFoundation . About Amgen … benefits and synergies of collaborations with any other company, including BeiGene, Ltd., or the Otezla ® (apremilast) acquisition, including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates of …

Biosimilars

3 Best Performing Biotech Funds So Far in 2019 - December 3, 2019 - Zacks.com | 12/3/2019

… than-average performance of the industry has been mainly driven by mergers and acquisitions, initial public offerings (IPOs), introduction of biosimilars, collaborative operations, rising use of AI and new job opportunities. In fact, the major … this year. In October, Amgen announced a strategic collaboration with BeiGene to help the former expand its oncology presence in China. Earlier this year, Biogen and C4 Therapeutics announced a collaboration to evaluate the use …

Precision Medicine

The State of Personalized/Precision Medicine in 2019 (Q4) - ResearchAndMarkets.com | Business Wire | 12/3/2019

DUBLIN- The “The State of Personalized/ Precision Medicine” report has been added to ResearchAndMarkets.com’s offering. This report covers current and future challenges for the development and launch of these medicines, focusing on challenges with transitioning … Companies Mentioned Adaptive Biotechnologies Ambry Genetics Corp. Astellas AstraZeneca Baxalta BeiGene Berg Health BrainStorm Cell Therapeutics Bristol-Myers Squibb Catabasis Clovis Oncology Denovo Biopharma Eli Lilly Foundation Medicine GenSight Biologics IgDraSol Ignyta Kiadis Konica Minolta …

National Cancer Institute

Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019

… B-ALL) were accepted as a late-breaking abstract. AALL1331 is sponsored by the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI), part of the National Institutes of Health, and is conducted by … benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates …

National Institutes of Health

Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019

… breaking abstract. AALL1331 is sponsored by the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI), part of the National Institutes of Health, and is conducted by the NCI-funded COG. Amgen provided BLINCYTO … benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates …

Healthcare Cost Containment

Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019

… deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

Cancer Therapy

Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019

… relapse of childhood B-lymphoblastic leukemia (B-ALL) were accepted as a late-breaking abstract. AALL1331 is sponsored by the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI), part of the National Institutes … benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates …

Clinical Validation

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma [Research Articles] | 12/2/2019

… a consultant at Novartis, Ipsen, and Eisai and has received honoraria from the speakers bureaus of MSD, Pfizer, Ipsen, Bayer, and Eisai. T. Macarulla reports receiving commercial research support from Celgene, AstraZeneca, and BeiGene, has received honoraria from the speakers bureaus of Celgene, Raffo, Serviere, Incyte, and Sanofi, and is an unpaid consultant/advisory board member for Celgene, Serviere, Incyte, Amgen, and AstraZeneca. J.-W. Park is an advisor at …

Gene Therapy

The return of the megamerger | 12/2/2019

… got rid of businesses that fell outside their core mandate of discovering new medicines. A number of midsize cancer- and gene therapy–focused biotech firms were gobbled up, and more are likely to be absorbed … for a roughly 20% stake in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact. Novartis pays Takeda Pharmaceutical $3.4 billion to acquire the dry …

Clinical Collaboration

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress | The Wapakoneta Daily News | 11/22/2019

… mini oral presentation by Dr. Do-Youn Oh, study investigator and Professor at Seoul National University, at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore. Zymeworks and its collaborator BeiGene, Ltd. plan to advance ZW25 into potentially registration-enabling global studies in HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA), based on these durable and consistent clinical data. “The promising ZW25 data at ESMO …

CAR-T

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks’ Positive Readout, Enanta Misses Earnings Estimate | Benzinga | 11/22/2019

… completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue … company said the funds will support the development of its CAR-T candidates, including CYAD-01 and CYAD-02 for the treatment of relapsed/refractory acute myeloid leukemia, as well as next-gen approaches in …

Specialty Pharmacy Network

BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360 | Malvern Daily Record | 11/21/2019

Onco360 ® , the nation’s largest independent Oncology Pharmacy, has been selected by BeiGene to be a specialty pharmacy network partner for BRUKINSA ™ (zanubrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. “The approval of BRUKINSA as a second-line therapy option for patients with relapsed and refractory MCL is an important advancement in fighting this devastating disease,” said Paul …

American Heart Association

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack | PR Newswire | 11/16/2019

… was 25% compared to 15% in those patients with a more distant MI. The results will be presented at the American Heart Association Annual Scientific Sessions in Philadelphia on Monday, Nov. 18 . “Nearly 1 in … benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates …

Mental Health

Friday, November 15, 2019 | Kaiser Health News | 11/15/2019

… Veteran Suicides Top Democrats running for president in 2020 are vowing to reduce veteran suicide rates by improving access to mental health care and making improvements to the Department of Veterans Affairs (VA). The issue … granted approval to a blood cancer drug from Beijing-based BeiGene Ltd., paving the way for American patients to access a Chinese cancer therapy for the first time. The accelerated approval – ahead of even China’s …

Center for Drug Evaluation and Research

Friday, November 15, 2019 | Kaiser Health News | 11/15/2019

… U.S. Patient Use The U.S. Food and Drug Administration has granted approval to a blood cancer drug from Beijing-based BeiGene Ltd., paving the way for American patients to access a Chinese cancer therapy for … Ashley, director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research, said in the release. “In this case, Dollar Tree has the ultimate responsibility to ensure that it does not …

Medicare

Friday, November 15, 2019 | Kaiser Health News | 11/15/2019

… an election where the industry often serve as the common enemy. In other news from the 2020 campaign trail: the “Medicare for All” debate, veteran suicides, and emergency preparedness. Deval Patrick’s Ties To Health-Care … granted approval to a blood cancer drug from Beijing-based BeiGene Ltd., paving the way for American patients to access a Chinese cancer therapy for the first time. The accelerated approval – ahead of even China’s …

Genomics

Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors | PR Newswire | 11/15/2019

… and performing landmark outcomes research. DCRI research spans multiple disciplines, from pediatrics to geriatrics, primary care to subspecialty medicine, and genomics to proteomics. The DCRI also is home to the Duke Databank for Cardiovascular Diseases … benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates …

Population Health

BGNE Soars, DRNA Hits New High On Roche Deal, FDA Heeds REPH’s Request | Markets Insider | Business Insider | 11/1/2019

… RTTNews) - Today’s Daily Dose brings you news about the reverse split of Applied DNA; the global strategic oncology collaboration between BeiGene and Amgen; better-than-expected earnings reported by Bio-Rad; upcoming catalysts of bluebird … CLNH. Clinigence is a pioneer in clinical quality reporting and population health analytics, and iGambit wholly owns HealthDatix, a healthcare technology company with a platform for optimizing annual wellness visits/health risk assessments and chronic …

Biotechnology Innovation Organization

BeiGene Chief Executive Officer John V. Oyler Elected to BIO Board of Directors - NASDAQ.com | 6/5/2019

June 04, announced that the Biotechnology Innovation Organization (BIO) has elected John V. Oyler, Co-Founder, Chief Executive Officer, and Chairman of BeiGene, to its Board of Directors as well as to its Health Section Governing Board. The Health Section Governing Board addresses policy and regulatory issues, and related subjects of significance to the biotechnology industry. John V. Oyler, Co-Founder, Chairman & CEO of BeiGene “It is my privilege to …

Novartis

Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development - Business Wire | 5/11/2020

… BeiGene, Ltd. where she oversaw development programs aimed to evaluate an immuno-oncology combination therapy targeting solid tumors. She also held the role of Vice President of Clinical Development at Jounce Therapeutics where she managed the company’s early development program and guided clinical trial execution. In addition, Dr. Thomas held leadership clinical development and medical roles in oncology at Bristol-Myers Squibb, Novartis, GlaxoSmithKline, and Amgen. “I am thrilled to …

Bristol-Myers Squibb

Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development - Business Wire | 5/11/2020

… BeiGene, Ltd. where she oversaw development programs aimed to evaluate an immuno-oncology combination therapy targeting solid tumors. She also held the role of Vice President of Clinical Development at Jounce Therapeutics where she managed the company’s early development program and guided clinical trial execution. In addition, Dr. Thomas held leadership clinical development and medical roles in oncology at Bristol-Myers Squibb, Novartis, GlaxoSmithKline, and Amgen. “I am thrilled to …

Bristol-Myers

Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development - Business Wire | 5/11/2020

… BeiGene, Ltd. where she oversaw development programs aimed to evaluate an immuno-oncology combination therapy targeting solid tumors. She also held the role of Vice President of Clinical Development at Jounce Therapeutics where she managed the company’s early development program and guided clinical trial execution. In addition, Dr. Thomas held leadership clinical development and medical roles in oncology at Bristol-Myers Squibb, Novartis, GlaxoSmithKline, and Amgen. “I am thrilled to …

GlaxoSmithKline

Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development - Business Wire | 5/11/2020

… BeiGene, Ltd. where she oversaw development programs aimed to evaluate an immuno-oncology combination therapy targeting solid tumors. She also held the role of Vice President of Clinical Development at Jounce Therapeutics where she managed the company’s early development program and guided clinical trial execution. In addition, Dr. Thomas held leadership clinical development and medical roles in oncology at Bristol-Myers Squibb, Novartis, GlaxoSmithKline, and Amgen. “I am thrilled to …

Celgene

BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting | 4/30/2020

Developmental Therapeutics—Immunotherapy Poster Session Lead Author Jianming Xu, M.D., General Hospital of Chinese People’s Liberation Army, China About BeiGene BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing … market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter …

Pfizer

#FierceMadness: Big brands and underdogs—Onpattro and Jeuveau included—make the Sweet 16 cut | FiercePharma | 3/30/2020

… Pfizer’s Vyndaqel and Alexion’s Ultomiris top Novartis’ Adakveo. In the battle of the vowels, as one voter put it, Jeuveau narrowly beat Novartis’ Beovu. And Jeuveau not only won the vowels race for some, but it also pleased the Francophiles, who commented, “Sounds like a great French tennis player” and “French honors student … sounds lovely!” In Oncology, BeiGene’s Brukinsa posted a win over Bayer’s Nubeqa—a surprise, considering the general …

Merck

#FierceMadness: Big brands and underdogs—Onpattro and Jeuveau included—make the Sweet 16 cut | FiercePharma | 3/30/2020

… for voters, although other associations, like “scooter-share company,” also won Motegrity votes. In the same division, Roche’s Xofluza topped Merck’s Ervebo, with voters favoring the flu treatment with comments that indicated we can’t escape … tennis player” and “French honors student … sounds lovely!” In Oncology, BeiGene’s Brukinsa posted a win over Bayer’s Nubeqa—a surprise, considering the general love that any “q” names seem to get. In this case, though …

AbbVie

#FierceMadness: Big brands and underdogs—Onpattro and Jeuveau included—make the Sweet 16 cut | FiercePharma | 3/30/2020

… standing, with drugs from both big and small pharma companies still in the hunt. Big winners from Big Pharma include AbbVie’s Skyrizi and Roche’s Xofluza, while smaller pharma brands still vying for the top title … tennis player” and “French honors student … sounds lovely!” In Oncology, BeiGene’s Brukinsa posted a win over Bayer’s Nubeqa—a surprise, considering the general love that any “q” names seem to get. In this case, though …

Gilead Sciences

Global chemical effects of the microbiome include new bile-acid conjugations | Nature | 2/26/2020

… BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Progenity, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB …

Incyte

Global chemical effects of the microbiome include new bile-acid conjugations | Nature | 2/26/2020

… BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Progenity, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB …

Biogen

5 Best-Performing Biotech Mutual Funds of 2019 - January 22, 2020 - Zacks.com | 1/22/2020

BeiGene and Biogen’s partnership with C4 Therapeutics were some crucial alliances last year. Owing to these factors, major biotech ETFs and indexes performed impressively in 2019. Specifically, the SPDR S&P Biotech ETF (XBI), iShares Nasdaq Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB) and NASDAQ Biotechnology Index (NBI) gained 30.5%, 23%, 41.8% and 22.9%, respectively. 5 Top Biotech Mutual Funds We have, therefore, selected five biotech mutual funds that …

Loxo Oncology

5 Best-Performing Biotech Mutual Funds of 2019 - January 22, 2020 - Zacks.com | 1/22/2020

… kept the space in investors’ focus. Bristol-Myers Squibb’s acquisition of Celgene Corporation and Eli Lilly and Company’s acquisition of Loxo Oncology were some of the major deals that took place last year. Second, the … as major game changers for the industry. Amgen’s collaboration with BeiGene and Biogen’s partnership with C4 Therapeutics were some crucial alliances last year. Owing to these factors, major biotech ETFs and indexes performed impressively in …

Seattle Genetics

FiercePharmaAsia—AZ-Daiichi’s fast Enhertu nod; Astellas’ 2 partnered approvals, CAR-T buy | 1/3/2020

… 2 partnered approvals, CAR-T buy by Jan 3, 2020 11:00am Daiichi Sankyo and AstraZeneca as well as Astellas and Seattle Genetics made our end-of-year news. (Google) Asian drugmakers had a few busy … Prevnar 13 and Merck & Co.’s Gardasil, as well as BeiGene’s PD-1 inhibitor tislelizumab and Zai Lab’s Zejula, licensed from GlaxoSmithKline. 1. AstraZeneca, Daiichi notch blockbuster FDA nod for breast cancer med Enhertu Daiichi …

Amgen

6 recent drug company acquisitions | Becker’s Hospital Review | 12/4/2019

Since Nov. 1, the following drugmakers have announced or completed acquisitions: Note: This is not an exhaustive list. Deals were reported by Becker’s Hospital Review and are presented in the order in which they were reported. Amgen is investing $2.7 billion in a Chinese drugmaker, BeiGene, giving it a 20.5 percent stake in the company. More articles on pharmacy: Parents in Europe crowdsource $2.7M to buy world’s most expensive drug …

Novo Nordisk

Global Chronic Disease Management Markets to 2024, Featuring Profiles of Leading Players Roche, AbbVie, Johnson & Johnson, Bristol-Myers Squibb, Merck, GlaxoSmithKline, and More | The Wapakoneta Daily News | 12/3/2019

… Pharmacare Astrazaneca Plc Astellas Pharma Inc. Athersys Audentes Therapeutics Axiobionics Axsome Therapeutics Ayogo Health Bausch Health Bayer Ag Bespak Europe Beigene Bioxcel Therapeutics Biosensics Bioserenity Biotronik Gmbh Biotricity Biovotion Bodytel Boehringer Ingelheim Boston Scientific Bristol … Neofect Co., Ltd. Neurocrine Biosciences Neurometrix Inc. Neurovigil Inc. Novartis Novo Nordisk Novasom Inc. Nucana Omada Health Inc. Omron Corp. Omnicell Inc. Ono Pharmaceutical Co., Ltd. Orion Pharma Ltd. Orpyx Medical Technologies Otsuka Pharmaceuticals Pacira …

Adaptive Biotechnologies

The State of Personalized/Precision Medicine in 2019 (Q4) - ResearchAndMarkets.com | Business Wire | 12/3/2019

Adaptive Biotechnologies Ambry Genetics Corp. Astellas AstraZeneca Baxalta BeiGene Berg Health BrainStorm Cell Therapeutics Bristol-Myers Squibb Catabasis Clovis Oncology Denovo Biopharma Eli Lilly Foundation Medicine GenSight Biologics IgDraSol Ignyta Kiadis Konica Minolta Loxo Oncology Marinus Merck & Co. NantPharma Nebula Genomics Novartis Pfizer Precision Biosciences Retrophin Revolution Medicines Rhythm Pharmaceuticals Roche Sanofi Sarepta Sutro Biopharma Takeda Vertex Visterra Voluntis For more information about this report visit https://www.researchandmarkets.com/r/tmvsjh …

Eli Lilly

3 Best Performing Biotech Funds So Far in 2019 - December 3, 2019 - Zacks.com | 12/3/2019

… completed in November 2019. Takeda Pharmaceutical Company Limited completed the acquisition of Shire in January. In the very next month, Eli Lilly and Company acquired Loxo Oncology. This acquisition extended the scope of the former’s … this year. In October, Amgen announced a strategic collaboration with BeiGene to help the former expand its oncology presence in China. Earlier this year, Biogen and C4 Therapeutics announced a collaboration to evaluate the use …

Allergan

The return of the megamerger | 12/2/2019

… in a deal worth $13.4 billion. Amgen pays $2.7 billion for a roughly 20% stake in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact … immunology franchise, announced plans to buy the specialty pharmaceutical firm Allergan. And Pfizer unveiled plans to combine its Upjohn generics business with Mylan, forming a stand-alone firm with about $20 billion in annual revenues …

Array BioPharma

The return of the megamerger | 12/2/2019

… in a deal worth $13.4 billion. Amgen pays $2.7 billion for a roughly 20% stake in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact … its innovative medicine business with the $11.4 billion acquisition of Array BioPharma . A few factors motivated this year’s surge in activity, says Glenn Hunzinger, pharma and life sciences deals leader at the consulting firm PwC …

Gilead

China gives Merck, BMS cold shoulder on reimbursement list as PD-1 battle enters new phase | FiercePharma | 12/2/2019

… Drugmakers cut prices by an average 60.7% to win coverage in the world’s second-largest pharmaceutical market. AbbVie, AstraZeneca, Bayer, Gilead Sciences, Johnson & Johnson, Novartis, Roche and Sanofi are among multinational pharma companies to have … was not eligible for this round of price talks. And BeiGene’s tislelizumab awaits a decision in cHL as well. Officially launched on Mar. 9, Tyvyt racked up sales of CNY 331.6 million ($47.1 million) by …

Johnson & Johnson

China gives Merck, BMS cold shoulder on reimbursement list as PD-1 battle enters new phase | FiercePharma | 12/2/2019

… prices by an average 60.7% to win coverage in the world’s second-largest pharmaceutical market. AbbVie, AstraZeneca, Bayer, Gilead Sciences, Johnson & Johnson, Novartis, Roche and Sanofi are among multinational pharma companies to have reached deals … was not eligible for this round of price talks. And BeiGene’s tislelizumab awaits a decision in cHL as well. Officially launched on Mar. 9, Tyvyt racked up sales of CNY 331.6 million ($47.1 million) by …

AstraZeneca

China gives Merck, BMS cold shoulder on reimbursement list as PD-1 battle enters new phase | FiercePharma | 12/2/2019

… reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage in the world’s second-largest pharmaceutical market. AbbVie, AstraZeneca, Bayer, Gilead Sciences, Johnson & Johnson, Novartis, Roche and Sanofi are among multinational pharma companies … was not eligible for this round of price talks. And BeiGene’s tislelizumab awaits a decision in cHL as well. Officially launched on Mar. 9, Tyvyt racked up sales of CNY 331.6 million ($47.1 million) by …

McKesson

Global Microneedles & Needle-Free Injection Systems/Jet Injectors Market, 2019-2030 | PR Newswire | 11/28/2019

Global Microneedles & Needle-Free Injection Systems/Jet Injectors Market, 2019-2030 News provided by Research and Markets Nov 28, 2019, 08:30 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering. Chronic clinical conditions, such as diabetes, cardiovascular disorders, certain types of neurological disorders, and cancer, are considered to …

Vizient

Global Microneedles & Needle-Free Injection Systems/Jet Injectors Market, 2019-2030 | PR Newswire | 11/28/2019

Global Microneedles & Needle-Free Injection Systems/Jet Injectors Market, 2019-2030 News provided by Research and Markets Nov 28, 2019, 08:30 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering. Chronic clinical conditions, such as diabetes, cardiovascular disorders, certain types of neurological disorders, and cancer, are considered to …

ImmunoGen

Global Microneedles & Needle-Free Injection Systems/Jet Injectors Market, 2019-2030 | PR Newswire | 11/28/2019

Global Microneedles & Needle-Free Injection Systems/Jet Injectors Market, 2019-2030 News provided by Research and Markets Nov 28, 2019, 08:30 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering. Chronic clinical conditions, such as diabetes, cardiovascular disorders, certain types of neurological disorders, and cancer, are considered to …

SVB Leerink

The return of the megamerger | 12/2/2019

… of deal: Cholesterol-lowering drug in late-stage studies Source: Companies According to an analysis done by the investment firm SVB Leerink, global pharmaceutical merger and acquisition activity is on track to hit a 10 … for a roughly 20% stake in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact. Novartis pays Takeda Pharmaceutical $3.4 billion to acquire the dry …

Maxim Group

Maxim Group Maintains Their Buy Rating on BeiGene (BGNE) | 11/14/2019

Maxim Group Maintains Their Buy Rating on BeiGene (BGNE) Carrie Williams - November 14, 2019, 7:39 AM EDT SHARE ON: In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BeiGene ( BGNE ), with a price target of $210.00 . The company’s shares closed last Monday at $197.30, close to its 52-week high of $200.00. According to TipRanks.com , McCarthy is currently ranked with no stars on a …

Zacks Equity Research

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene | 11/12/2019

… Release Chicago, IL –November 12, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial … announced that it has entered into a strategic collaboration with BeiGene to expand its oncology presence in China. Biogen and C4 Therapeutics announced in January that they have entered into a strategic collaboration to examine …

Matrix Partners

Week In Review: AstraZeneca Announces $1 Billion Fund For China Life Science Startups | Seeking Alpha | 11/10/2019

… the new biopharmas. The company will share its expertise with the startups and may choose to invest further in them. BeiGene (NASDAQ: BGNE ) [HK:06160] of Beijing announced a $160 million agreement for China/Asia … million in a series C funding that was led by Matrix Partners China, which also led Peijia’s A round. Founded in 2012, Peijia claims to have developed China’s first cardiovascular drug-eluting stent and intracranial …

Morgan Stanley

BeiGene Ltd (BGNE): Guggenheim Reconfirms Buy Rating Today, Has a Target of $205/Share | Finance Recorder | 11/4/2019

Posted by Doherty Rodney on November 4, 2019 at 5:33 am BeiGene Ltd (BGNE) Rating Reaffirmed In a research note shared with investors and clients on Friday, 1 November, The Buy rating of BeiGene Ltd … SRatingsIntel. The company was maintained on Friday, October 11 by Morgan Stanley. The stock of BeiGene, Ltd. (NASDAQ:BGNE) has “Buy” rating given on Thursday, June 20 by Maxim Group. Cowen & Co maintained it with …

Goldman Sachs

Amgen takes 20% stake in Chinese biotech BeiGene for $2.7 billion | CNBC | 10/31/2019

A researcher prepares a sample inside a laboratory at BeiGene Ltd.’s research and development center in Beijing, China, on Thursday, May 24, 2018. Gilles Sabrie Bloomberg Getty Images Biotechnology company Amgen announced Thursday it … we can. We do believe this is a global fight.” Goldman Sachs is acting as the financial advisor to Amgen, while Latham & Watkins is serving as a legal advisor. Morgan Stanley is acting as exclusive …

DuPont Capital Management

Dupont Capital Management Corp Sells 904 Shares of Beigene Ltd (NASDAQ:BGNE) | 9/13/2019

Dupont Capital Management Corp reduced its position in shares of Beigene Ltd (NASDAQ:BGNE) by 28.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,239 shares of the company’s stock after selling 904 shares during the quarter. Dupont Capital Management Corp’s holdings in Beigene were worth $278,000 as of its most recent SEC filing. A number of …

Bruker

Global Biomarkers Discovery Techniques and Applications Market Overview 2019-2021 with Profiles of 50+ Key Players & Industry Guide with Contact Details for 225 Companies | PR Newswire | 8/19/2019

… CH Enzymatic Hemoglobin A1c (A1c_E) Assay for Diabetes Development of New Ultra-High Field 18 Tesla MRI System by Bruker and Champalimaud Development of Diagnostic Tool for Molecular Biomarker Detection by GE and Indi … to Set up Metabolomics Platform in Qatar Myriad Genetics and BeiGene to Develop Companion Diagnostics for BeiGene’s BGB-290 PARP Inhibitor European Release of VeriSeq NIPT Solution by Illumina BacT/ALERT VIRTUO Blood Culture System …

Macquarie

Beigene (NASDAQ:BGNE) Receives New Coverage from Analysts at Macquarie | 7/28/2019

Macquarie assumed coverage on shares of Beigene (NASDAQ:BGNE) in a research note released on Friday, July 5th, The Fly reports. The firm issued an underperform rating on the stock. A number of other equities research analysts have also issued reports on the stock. Maxim Group set a $9.00 target price on shares of Pitney Bowes and gave the company a buy rating in a research note on Friday, May …

Citigroup

Beigene Ltd (NASDAQ:BGNE) Shares Sold by Citigroup Inc. | 6/23/2019

Beigene Ltd (NASDAQ:BGNE) Shares Sold by Citigroup Inc. Posted by Arthur Bond on Jun 23rd, 2019 Tweet Citigroup Inc. lessened its holdings in shares of Beigene Ltd (NASDAQ:BGNE) by 19.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,086 shares of the company’s stock after selling 17,505 shares during the quarter. Citigroup Inc. owned 0.12 …

Daiichi Sankyo

FiercePharmaAsia—Japan’s global first nods; Celgene hands back PD-1; China’s copycat invite | FiercePharma | 6/21/2019

… Daiichi Sankyo’s FLT3 inhibitor Vanflyta (quizartinib), a challenger to Astellas’ Xospata, has been cleared in Japan for relapsed/refractory FLT3-ITD acute myeloid leukemia. AstraZeneca also secured its first global approval for Breztri Aerosphere, a three-in-one chronic obstructive pulmonary disease inhaler that will go up against GlaxoSmithKline’s Trelegy Ellipta. 2. Celgene hands PD-1 tislelizumab med back to BeiGene, forfeiting $150M As the Bristol-Myers Squibb merger moves …

Merrill Lynch

Wall Street Brunch | Seeking Alpha | 6/9/2019

… Ives. Tesla closed on Friday at $206.32. Cannabis catalyst: HEXO’s ( OTC:HEXO ) earnings report is seen by Bank of America Merrill Lynch as a potential catalyst for the cannabis sector with Quebec trends expected to … Global Blood Therapeutics (NASDAQ: GBT ), bluebird bio (NASDAQ: BLUE ) and BeiGene (NASDAQ: BGNE ). The FDA action date for Merck’s (NYSE: MRK ) Keytruda treatment also arrives this week. Goldman Sachs 40th Annual Global Healthcare Conference The …

Harvard Medical School

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack | PR Newswire | 11/16/2019

… member and a senior investigator at the TIMI Study Group at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School . “These results demonstrate the importance of intensive lipid-lowering therapy in the … benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates …

How measles infections can wipe away immunity to other diseases | STAT | 10/31/2019

… forgot what it once knew,” said Stephen Elledge, senior author of the Science paper and a professor of genetics at Harvard Medical School. The second paper , from researchers in Europe, was simultaneously published in the … several years after a measles outbreak. Amgen acquires stake in BeiGene to expand cancer drug business to China Mina and Elledge both suggested doctors may want to consider re-vaccinating children and perhaps even adults …

University of Texas MD Anderson Cancer Center

U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy | BioSpace | 11/15/2019

CAMBRIDGE, Mass. and BEIJING, China, Nov. 14, 2019 (GLOBE NEWSWIRE) – BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for … of Lymphoma and Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and clinical trial investigator. “The approval of BRUKINSA as a second line therapy represents an important advancement for …

U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy | Globe Newswire | 11/14/2019

This marks the first FDA approval for BeiGene - 84% of patients taking BRUKINSA achieved an overall response 1 - BRUKINSA is the only FDA-approved BTK inhibitor shown to deliver 100% median occupancy in peripheral blood … of Lymphoma and Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and clinical trial investigator. “The approval of BRUKINSA as a second line therapy represents an important advancement for …

The University of Texas MD Anderson Cancer Center

U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy | BioSpace | 11/15/2019

CAMBRIDGE, Mass. and BEIJING, China, Nov. 14, 2019 (GLOBE NEWSWIRE) – BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for … Department of Lymphoma and Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and clinical trial investigator. “The approval of BRUKINSA as a second line therapy represents an important advancement …

U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy | Globe Newswire | 11/14/2019

This marks the first FDA approval for BeiGene - 84% of patients taking BRUKINSA achieved an overall response 1 - BRUKINSA is the only FDA-approved BTK inhibitor shown to deliver 100% median occupancy in peripheral blood … Department of Lymphoma and Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and clinical trial investigator. “The approval of BRUKINSA as a second line therapy represents an important advancement …

MD Anderson Cancer Center

FiercePharmaAsia—Amgen-BeiGene $2.7B tie-up; AZ’s China projects; controversial Alzheimer’s drug | FiercePharma | 11/8/2019

Amgen is tapping into BeiGene’s R&D and marketing capabilities in China by paying $2.7 billion for a 20.5% stake in the Chinese biotech. AstraZeneca said it’s stepping up its commitment to China with a … 2021 pivotal trial Takeda has struck a deal with the MD Anderson Cancer Center to access up to four CAR-NK cell therapies, including candidates against CD19 and BCMA. Compared to existing CAR-T drugs …

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature | 10/30/2019

… BeiGene, Bioatla, Biothera, Celldex, Celgene, Ciclomed, Curegenix, Curis, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Exelixis, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Jounce, Kolltan, Loxo, MedImmune, Millennium, Merck, Mirna Therapeutics, the National Institutes of Health, Novartis, OncoMed, Oncothyreon, Precision Oncology, Regeneron, Rgenix, Ribon, Strategia, Syndax, Taiho, Takeda, Tarveda, Tesaro, Tocagen, Turning Point Therapeutics, the UT MD Anderson Cancer Center and Vegenics; receives royalties from Wolters Kluwer; and has also …

Novant Health

Amgen invests $2.7B in Chinese drugmaker | Becker’s Hospital Review | 11/1/2019

Amgen is investing $2.7 billion in a Chinese drugmaker, BeiGene, giving it a 20.5 percent stake in the company, according to CNBC . BeiGene, which manufactures molecularly targeted and immuno-oncology drugs to treat cancer, plans … said it will eliminate 500 U.S. jobs by Jan. 3. Novant Health to open health clinics inside WalgreensNovant Health, a 15-hospital system in Winston-Salem, N.C., will open retail health clinics inside several Walgreens …

Pharmacy Times Continuing Education™ Presents Three Continuing Education-accredited Oncology Webinars in May | Business Wire | 4/23/2019

… 8 P.M. ET. The faculty presenter for this webinar will be Eric Chow, Pharm.D., BCOP, system pharmacy oncology manager at Novant Health. Chow will provide pharmacists with education on the changing landscape, including use of … Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC; and BeiGene Ltd. To register, click here . Safe and Efficacious Use of Immunotherapy Agents: Pharmacist-Driven Strategies to Improve Patient Outcomes, available Thursday, May 23, at …

HCA

Oct 29, 2019 - JGP Global Gestao de Recursos Ltda. Buys MercadoLibre Inc, Wells Fargo, StoneCo, Sells Vale SA, Facebook Inc, Grupo Financiero Galicia SA - GuruFocus.com | 10/29/2019

… UNH , PFE , A , SYK , TMO , VRTX , ANTM , SAGE , ARGX , ISRG , BDX , LLY , DHR , NBIX , CI , WCG , AMGN , AZN , CELG , CNC , HCA , COO , HOLX , TFX , HUM , REGN , MRK , Reduced Positions: VALE , FB , OIBR.C , OIBRQ , Sold Out … was 0.15%. The holding were 17,505 shares as of . Added: BeiGene Ltd ( BGNE ) JGP Global Gestao de Recursos Ltda. added to a holding in BeiGene Ltd by 27.95%. The purchase prices were between $120.61 and …

China’s Healthcare Market is Expected to Grow as Government Changes Regulations | PR Newswire | 11/7/2017

Share this article NEW YORK , November China’s healthcare market is projected to grow at an unprecedented CAGR of about 12% to reach $1 trillion by 2020, or up from $357 billion in 2011 as estimated … MediTech Limited (NASDAQ: HCM), iKang Healthcare Group, Inc. (NASDAQ: KANG), BeiGene, Ltd. (NASDAQ: BGNE), Zai Lab Ltd. (NASDAQ: ZLAB ) For years, local and multinational drug manufacturers have struggled with delayed approvals in China . Bloomberg’s report …

Greenville Health System

Pharmacy Times Continuing Education™ Presents Three Continuing Education-accredited Oncology Webinars in May | Business Wire | 4/23/2019

BeiGene Ltd. To register, click here . Safe and Efficacious Use of Immunotherapy Agents: Pharmacist-Driven Strategies to Improve Patient Outcomes, available Thursday, May 23, at 6 and 8 P.M. ET. The faculty presenter for this webinar will be Christopher J. Campen, Pharm.D., BCPS, BCOP, clinical oncology pharmacist at Greenville Health System Cancer Institute and a clinical assistant professor at the University of South Carolina School of Medicine Greenville. Campen will …

Pharmacy Times Continuing Education™ Presents Three Continuing Education-accredited Oncology Webinars in May | Business Wire | 4/23/2019

BeiGene Ltd. To register, click here . Safe and Efficacious Use of Immunotherapy Agents: Pharmacist-Driven Strategies to Improve Patient Outcomes, available Thursday, May 23, at 6 and 8 P.M. ET. The faculty presenter for this webinar will be Christopher J. Campen, Pharm.D., BCPS, BCOP, clinical oncology pharmacist at Greenville Health System Cancer Institute and a clinical assistant professor at the University of South Carolina School of Medicine Greenville. Campen will …

Aetna

Can Pharmacy Services Drive CVS Health’s (CVS) Q2 Earnings? | Zacks | 8/5/2019

… should continue in the second quarter as well. Last but not the least, the company earlier noted that post the Aetna integration, its Pharmacy Services segment’s current-year figures will be affected by two important … an Earnings ESP of +4.00% and a Zacks Rank 2. BeiGene, Ltd. ( BGNE - Free Report ) has an Earnings ESP of +8.55% and a Zacks Rank 1. You can see the complete list of today’s Zacks …

Can Pharmacy Services Drive CVS Health’s (CVS) Q2 Earnings? - August 5, 2019 - Zacks.com | 8/5/2019

… should continue in the second quarter as well. Last but not the least, the company earlier noted that post the Aetna integration, its Pharmacy Services segment’s current-year figures will be affected by two important … an Earnings ESP of +4.00% and a Zacks Rank 2. BeiGene, Ltd. ( BGNE - Free Report ) has an Earnings ESP of +8.55% and a Zacks Rank 1. You can see the stocks here . Would …

John Oyler

BeiGene CEO on Coronavirus Impact, China Biopharma, Product Pipeline [Video] | 4/7/2020

Bloomberg UK 7 April 2020 Apr.06 – John Oyler, chairman and chief executive officer at BeiGene Ltd., discusses how coronavirus has impacted the business and his outlook for China’s Biopharma sector. He speaks on “Bloomberg Markets: China Open …

Angus Liu

Amgen wades deeper into Asia with full control of an Astellas Japanese JV | 1/23/2020

Amgen wades deeper into Asia with full control of an Astellas Japanese JV by Angus Liu Jan 23, 2020 10:57am Amgen is purchasing the remaining 49% share it doesn’t yet have in a Japanese joint … The move comes on the heels of a $2.7 billion BeiGene tie-up, a large part of which also ends seven years after commercialization. Together, they represent Amgen’s growing interest in the Asia market, from …

Gang Yu

111 Unveils New Video on The Impact of Chinese Policies to Medical Industry | Markets Insider | Business Insider | 1/19/2020

… Gang Yu, Co-Founder and Executive Chairman of 111, Inc. Dr. Yu will moderate a discussion with Dr. Xiaobin Wu , President of BeiGene Ltd, and Dr. Darren Ji , CEO of Elpiscience Biopharma, Ltd. Tencent video link: https://v.qq.com/x/page/h3052n5gvqw.html? The Impact of Chinese Policies to Medical Industry will feature: Impacts of China’s healthcare reform on the industry: driving a market switch from public hospitals to retail channels and …

Laura Wood

The State of Personalized/Precision Medicine in 2019 (Q4) - ResearchAndMarkets.com | Business Wire | 12/3/2019

BeiGene Berg Health BrainStorm Cell Therapeutics Bristol-Myers Squibb Catabasis Clovis Oncology Denovo Biopharma Eli Lilly Foundation Medicine GenSight Biologics IgDraSol Ignyta Kiadis Konica Minolta Loxo Oncology Marinus Merck & Co. NantPharma Nebula Genomics Novartis Pfizer Precision Biosciences Retrophin Revolution Medicines Rhythm Pharmaceuticals Roche Sanofi Sarepta Sutro Biopharma Takeda Vertex Visterra Voluntis For more information about this report visit https://www.researchandmarkets.com/r/tmvsjh Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press …

David M. Reese

Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019

… regimen has the potential to be practice-changing for the treatment of patients with relapsed or refractory multiple myeloma,” said David M. Reese , M.D., executive vice president of Research and Development at Amgen. Additionally, data … benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates …

Brad Loncar

China gives Merck, BMS cold shoulder on reimbursement list as PD-1 battle enters new phase | FiercePharma | 12/2/2019

… a green light in cHL in late May and therefore was not eligible for this round of price talks. And BeiGene’s tislelizumab awaits a decision in cHL as well. Officially launched on Mar. 9, Tyvyt … from the reimbursement authorities.” Biotech investor and Loncar Investments CEO Brad Loncar also tweeted that Elunate “[r]ightfully should be the type of R&D that is rewarded,” and that its inclusion in NRDL “sends …

Ali Tehrani

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress | The Wapakoneta Daily News | 11/22/2019

… BeiGene, Ltd. plan to advance ZW25 into potentially registration-enabling global studies in HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA), based on these durable and consistent clinical data. “The promising ZW25 data at ESMO Asia further build momentum for the expanding footprint of our ZW25 clinical development program with BeiGene,” said Ali Tehrani, Ph.D., President and CEO of Zymeworks. “Cancer is a global fight, and this strong …

Paul Jardina

BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360 | Malvern Daily Record | 11/21/2019

Onco360 ® , the nation’s largest independent Oncology Pharmacy, has been selected by BeiGene to be a specialty pharmacy network partner for BRUKINSA ™ (zanubrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. “The approval of BRUKINSA as a second-line therapy option for patients with relapsed and refractory MCL is an important advancement in fighting this devastating disease,” said Paul …

Jessica Akopyan

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack | PR Newswire | 11/16/2019

… deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the … these uses. CONTACT: Amgen, Thousand Oaks Trish Hawkins , 805-447-5631 (media) Jessica Akopyan , 805-447-0974 (media) Arvind Sood , 805-447-1060 (investors) References Jernberg T, et al. Eur Heart J . 2015;36:1163-1170. Goldstein JL, et al. Arterioscler Thromb Vasc …

Arvind Sood

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack | PR Newswire | 11/16/2019

… deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaboration with any other company, including BeiGene, Ltd., or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the … Thousand Oaks Trish Hawkins , 805-447-5631 (media) Jessica Akopyan , 805-447-0974 (media) Arvind Sood , 805-447-1060 (investors) References Jernberg T, et al. Eur Heart J . 2015;36:1163-1170. Goldstein JL, et al. Arterioscler Thromb Vasc Biol. 2009;29(4 …

Darryl Sleep

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack – Company Announcement - FT.com | Financial Times | 11/16/2019

… are not managing one of the most important modifiable risk factors for a heart attack: high LDL-C 2 ,” said Darryl Sleep , M.D., senior vice president of Global Medical and chief medical officer at Amgen … benefits and synergies of collaboration with any other company, including BeiGene, Ltd. , or the acquisition of Otezla ® (apremilast), including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates …

Richard Pazdur

BeiGene nabs landmark FDA nod for Brukinsa, kicking off challenge against blockbuster Imbruvica | FiercePharma | 11/15/2019

by Angus Liu Nov 15, 2019 8:35am BeiGene has won accelerated FDA approval for BTK inhibitor and Imbruvica challenger Brukinsa in relapsed/refractory mantle cell lymphoma, marking marking the first FDA nod for a Chinese … based on China data in non-small cell lung cancer. Richard Pazdur, director of the FDA’s Oncology Center of Excellence, has previously indicated that the agency is willing to consider PD-1 inhibitors based solely …

Meghan Gutierrez

U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy | BioSpace | 11/15/2019

CAMBRIDGE, Mass. and BEIJING, China, Nov. 14, 2019 (GLOBE NEWSWIRE) – BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for … important advancement for the treatment of mantle cell lymphoma,” said Meghan Gutierrez, Chief Executive Officer for the Lymphoma Research Foundation. “Expanded treatment options can transform the patient experience and provide hope to people living with …

Donald Trump

Friday, November 15, 2019 | Kaiser Health News | 11/15/2019

… U.S. Patient Use The U.S. Food and Drug Administration has granted approval to a blood cancer drug from Beijing-based BeiGene Ltd., paving the way for American patients to access a Chinese cancer therapy for … NewsHour/ Inside A Shelter Holding Detained Migrant Kids Under President Donald Trump, the mass detention of migrant children has climbed to record numbers. Tonight, a joint investigation from FRONTLINE and The Associated Press called Kids …

Abraham L. Pomerantz

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE | Globe Newswire | 11/13/2019

… November 13, 2019 15:11 ET Source: Pomerantz LLP NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of BeiGene, Ltd. (“BeiGene” or the “Company”) (NASDAQ: BGNE). Such investors are advised to contact Robert … corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than …

Charles M. Baum

Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting – Company Announcement - FT.com | Financial Times | 11/10/2019

Charles M. Baum , M.D., Ph.D., President and Chief Executive Officer of Mirati. “In addition, we are evaluating sitravatinib in patients who have progressed on checkpoint therapy, including those with NSCLC and renal cell cancer, and we continue to expand development efforts of sitravatinib through our collaboration with BeiGene in multiple indications including NSCLC, renal cell cancer, hepatocellular cancer, ovarian cancer, and gastric cancer.” The ongoing Phase 2 clinical trial, an …

Pascal Soriot

FiercePharmaAsia—Amgen-BeiGene $2.7B tie-up; AZ’s China projects; controversial Alzheimer’s drug | FiercePharma | 11/8/2019

Amgen is tapping into BeiGene’s R&D and marketing capabilities in China by paying $2.7 billion for a 20.5% stake in the Chinese biotech. AstraZeneca said it’s stepping up its commitment to China with a slew of investments, as CEO Pascal Soriot and other Big Pharma execs dropped in on Shanghai for the China International Import Expo. China has granted conditional approval to a homegrown Alzheimer’s disease therapy, but the …

Sean McCarthy

CytomX Therapeutics, Inc. (CTMX) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… and News section of our website at cytomx.com. With me today are CytomX President, Chief Executive Officer, and Chairman, Dr. Sean McCarthy; CytomX newly appointed Chief Development Officer, Dr. Amy Peterson; and CytomX Vice President … senior roles, including Chief Medical Officer of immuno-oncology at BeiGene, where she created and led what is today recognized as a globally relevant oncology development organization. Prior to that, Amy was Vice President of …

Tamar Howson

MEI Pharma Reports First Quarter Fiscal Year 2020 Results and Operational Highlights | PR Newswire | 11/7/2019

… in combination with other therapies, like Rituxan® or zanubrutinib, an investigational BTK inhibitor as per our clinical collaboration agreement with BeiGene.” Recent Highlights In October 2019 , at MEI’s Investor and Analyst Event, the company reported … and 7.4 months (range 2.6-14.7 months), respectively. In July 2019 , Tamar Howson , M.S., MBA, a highly experienced business development executive with over 30 years of service in the pharmaceutical and biotechnology industry, joined the Board …

Bragar Eagel

Bragar Eagel & Squire, P.C. Is Investigating Merit Medical Systems, Baxter International, Under Armour, and BeiGene on Behalf of Stockholders and Encourages Investors to Contact the Firm | Globe Newswire | 11/6/2019

November 06, 2019 10:58 ET Source: Bragar Eagel & Squire NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against Merit Medical Systems, Inc. (NASDAQ: MMSI), Baxter International, Inc. (NYSE: BAX), Under Armour, Inc. (NYSE: UA, UAA), and BeiGene, Ltd. (NASDAQ: BGNE) on behalf of investors. Our investigation concerns whether these companies have violated the federal securities laws and …

Melissa Fortunato

BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of Stockholders and Encourages Investors to Contact the Firm | Business Wire | 11/2/2019

NEW YORK- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against BeiGene, Ltd. (NASDAQ: BGNE) on behalf of BeiGene stockholders. Our investigation concerns whether BeiGene has violated the federal … with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , or telephone at (212) 355-4648, or by filling out this contact form . There is no cost or obligation …

Michael Yee

Amgen pays $2.7B to enlist BeiGene as Chinese R&D partner | FierceBiotech | 11/1/2019

Nov 1, 2019 7:27am Amgen’s headquarters (Amgen) Amgen is paying $2.7 billion for a 20.5% stake in BeiGene. The investment will put BeiGene at the heart of Amgen’s efforts to develop oncology drugs for the … return an estimated $1B+ in revenues in the long-term,” Michael Yee and his colleagues wrote in a note to investors. BeiGene’s stock jumped 25% in after-hours trading on the Nasdaq. In Hong Kong …

Robert A. Bradway

Amgen Takes $2.7 Billion Stake in BeiGene to Expand Access to China - TheStreet | 11/1/2019

… BeiGene, Ltd. ( BGNE - Get Report ) to expand access to the Chinese pharmaceuticals market for its pipeline of cancer treatments, the companies said in a statement Thursday. The company will pay $174.85 per American depositary share of BeiGene. “This strategic collaboration with BeiGene will enable Amgen to serve significantly more patients by expanding our reach in the world’s most populous country,” Robert A. Bradway, Amgen’s chairman and chief executive officer, said …

Murdo Gordon

Amgen to buy $2.7 billion stake in Chinese biotech - MarketWatch | 10/31/2019

… company for $2.7 billion in cash, further demonstrating China’s emergence as a key market for foreign pharmaceutical companies. Amgen said BeiGene Ltd., a Beijing-based company focused on oncology, is going to commercialize certain Amgen … reimbursement programs, helped make it an attractive partner, according to Murdo Gordon, Amgen executive vice president for global commercial operations. Amgen was also impressed with the commercial infrastructure of BeiGene, which was founded in 2010 …

David Reese

Amgen acquires stake in BeiGene to expand cancer drug business to China | STAT | 10/31/2019

For BeiGene, the partnership bolsters its existing commercial operations in China, which already sells certain cancer medicines owned by Celgene ( CELG ), soon to be merged into Bristol-Myers Squibb. BeiGene is developing its own cancer … to bring the country in line with global standards,” said David Reese, Amgen’s R&D chief. “BeiGene has about 600 folks devoted to clinical development, which is going to accelerate our ability to develop our …